Localized Management of Soft Tissue Sarcoma Metastasis: A Review of a Multidisciplinary Approach
Meena Bedi1*, David M. King2, Hina Saeed1, Sean Tutton3, John A. Charlson4, Donald A. Hackbarth2, John C. Neilson2
Departments of Radiation Oncology1, Orthopaedic Surgery2, Interventional Radiology3, and Medical Oncology4 at the Medical College of Wisconsin.
The rate of distant metastasis from soft tissue sarcoma (STS) primaries ranges from 25-30%. The most common site of distant spread is hematogenously to the lung, however other sites of metastasis may occur, particularly in the liver and bone. Although systemic therapy has long been the foundation of treatment in patients, particularly with widespread disease, localized treatments of metastatic deposits have been increasingly used and shown to be safe and effective in the control of disease. Moreover, a combination of local and systemic therapy has been shown to improve survival. As the technical advancements in local therapy evolve, it is imperative that patients with metastatic STS are presented in a multidisciplinary setting to ensure that all disease aspects are evaluated and determination of the most effective therapies may be presented to each individual.